More about

Percutaneous Coronary Intervention

News
September 29, 2022
2 min read
Save

Top news of TCT 2022: PCI vs. CABG in multivessel CAD, PROTECTED TAVR results and more

Top news of TCT 2022: PCI vs. CABG in multivessel CAD, PROTECTED TAVR results and more

Healio and Cardiology Today have compiled a list of the most-read news in CV intervention from TCT 2022.

News
September 28, 2022
2 min read
Save

Long-term P2Y12 inhibitor monotherapy after PCI reduces bleeding at 3 years vs. DAPT

Long-term P2Y12 inhibitor monotherapy after PCI reduces bleeding at 3 years vs. DAPT

Long-term P2Y12 inhibition after PCI reduced bleeding at 3 years compared with dual antiplatelet therapy, with no significant differences observed for ischemic events, according to new data from the SMART-CHOICE trial.

News
September 26, 2022
2 min read
Save

PCSK9 inhibition before PCI for STEMI further reduces LDL on top of statin therapy

PCSK9 inhibition before PCI for STEMI further reduces LDL on top of statin therapy

BOSTON — PCSK9 inhibition before primary PCI for STEMI, on top of standard statin therapy, significantly lowered LDL at 6 weeks compared with sham control, according to the results of the EPIC-STEMI trial presented at TCT 2022.

News
September 23, 2022
2 min read
Save

At 2 years, superiority not confirmed for amphilimus-eluting stent in diabetes

At 2 years, superiority not confirmed for amphilimus-eluting stent in diabetes

BOSTON — After 2 years, PCI with amphilimus-eluting stents was noninferior to PCI with zotarolimus-eluting stents in patients with diabetes, not confirming the potential superiority signal observed at 1 year.

News
September 22, 2022
7 min watch
Save

VIDEO: Mehran reviews late-breaking science at TCT

VIDEO: Mehran reviews late-breaking science at TCT

BOSTON — In the Healio video exclusive, Roxana Mehran, MD, discussed late-breaking research presented at TCT 2022, as well as the benefits of convening the meeting in person following the COVID-19 pandemic.

News
September 22, 2022
1 min read
Save

REVIVED

REVIVED

PCI plus optimal medical therapy vs. optimal medical therapy alone in patients with severe LV dysfunction and extensive CAD.

News
September 20, 2022
2 min read
Save

FFR may predict 1-year outcomes, target vessel failure after PCI for multivessel CAD

FFR may predict 1-year outcomes, target vessel failure after PCI for multivessel CAD

BOSTON — Addition of fractional flow reserve to the classic SYNTAX score enabled researchers to identify patients with multivessel CAD undergoing PCI who would have similar 1-year outcomes as those who received CABG, a speaker reported.

News
September 20, 2022
2 min read
Save

In all-comers registry of left main CAD, CABG linked to better survival vs. PCI

In all-comers registry of left main CAD, CABG linked to better survival vs. PCI

BOSTON — In the all-comers SCAAR registry of patients with left main CAD who underwent revascularization in Sweden, PCI was associated with higher mortality rates compared with CABG.

News
September 19, 2022
3 min read
Save

Quantitative flow ratio-guided PCI improved 2-year MACE vs. angiography-based strategy

Quantitative flow ratio-guided PCI improved 2-year MACE vs. angiography-based strategy

BOSTON — Quantitative flow ratio-guided decision-making improved outcomes in patients with angina or recent MI vs. a standard angiography-guided strategy, regardless of whether preplanned PCI was performed or not, a speaker reported.

News
September 19, 2022
2 min read
Save

BEST: Few differences in long-term outcomes between PCI, CABG in multivessel CAD

BEST: Few differences in long-term outcomes between PCI, CABG in multivessel CAD

BOSTON — At a median follow-up of 11.8 years, most outcomes did not differ between PCI with an everolimus-eluting stent and CABG in patients with multivessel CAD, according to new data from the BEST trial.

View more